期刊
HUMAN GENE THERAPY
卷 33, 期 21-22, 页码 1109-1120出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/hum.2022.178
关键词
gene therapy; cancer; AAV; adenovirus; promoter; enhancer; oncolytics; immunotherapy; capsid engineering; rational design; directed evolution; therapeutic payloads
Advances in gene therapy, cancer genomics, and immunotherapy have provided more strategies for targeting human cancers using viral vectors. Improving the construction of viral vectors and selecting therapeutic payloads can achieve more precise treatment effects and overcome the challenge of delivering genes to the entire population of cancer cells. It is important to use advanced human cellular models for screening and evaluating novel candidates.
Advances in gene therapy, synthetic biology, cancer genomics, and patient-derived cancer models have expanded the repertoire of strategies for targeting human cancers using viral vectors. Novel capsids, synthetic promoters, and therapeutic payloads are being developed and assessed through approaches such as rational design, pooled library screening, and directed evolution. Ultimately, the goal is to generate precision-engineered viruses that target different facets of tumor cell biology, without compromising normal tissue and organ function. In this study, we briefly review the opportunities for engineering cancer selectivity into viral vectors at both the cell extrinsic and intrinsic level. Such stringently tumor-targeted vectors can subsequently act as platforms for the delivery of potent therapeutic transgenes, including the exciting prospect of immunotherapeutic payloads. These have the potential to eradicate nontransduced cells through stimulation of systemic anticancer immune responses, thereby side-stepping the inherent challenge of achieving gene delivery to the entire cancer cell population. We discuss the importance of using advanced primary human cellular models, such as patient-derived cultures and organoids, to enable rapid screening and triage of novel candidates using disease-relevant models. We believe this combination of improved delivery and selectivity, through novel capsids and promoters, coupled with more potent choices for the combinations of immunotherapy-based payloads seems capable of finally delivering innovative new gene therapies for oncology. Many pieces of the puzzle of how to build a virus capable of targeting human cancers appear to be falling into place.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据